38,668 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 38,668 shares of the company's stock, valued at approximately $788,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Victory Capital Management Inc. boosted its position in shares of Denali Therapeutics by 163.7% in the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after acquiring an additional 24,767 shares during the last quarter. FMR LLC grew its stake in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after buying an additional 7,596,508 shares during the period. Algert Global LLC increased its position in shares of Denali Therapeutics by 82.4% in the third quarter. Algert Global LLC now owns 48,630 shares of the company's stock worth $1,417,000 after acquiring an additional 21,975 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Denali Therapeutics in the 4th quarter valued at $514,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after acquiring an additional 14,324 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI traded up $0.58 during trading on Friday, reaching $14.78. 1,513,530 shares of the company's stock traded hands, compared to its average volume of 1,024,755. The stock has a market capitalization of $2.15 billion, a P/E ratio of -5.36 and a beta of 1.46. Denali Therapeutics Inc. has a 12 month low of $13.67 and a 12 month high of $33.33. The company has a 50 day moving average of $19.05 and a 200-day moving average of $23.25.

Remove Ads

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on DNLI shares. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective on the stock. Morgan Stanley began coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an "overweight" rating and a $33.00 price target on the stock. Oppenheimer lowered their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. HC Wainwright raised their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, William Blair restated an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $37.20.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now directly owns 178,580 shares of the company's stock, valued at $3,610,887.60. The trade was a 6.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steve E. Krognes sold 3,339 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the transaction, the director now owns 25,757 shares of the company's stock, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock worth $973,442 in the last 90 days. 7.90% of the stock is currently owned by company insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.